FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 352:29-38 January 6, 2005 Number 1 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Editorial by Ehrenstein, M. R. Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background Recent trials have demonstrated better outcomes with intensive than with moderate statin treatment. Intensive treatment produced greater reductions in both low-density lipoprotein (LDL) cholesterol and C-reactive protein (CRP), suggesting a relationship between these two biomarkers and disease progression.

Methods We performed intravascular ultrasonography in 502 patients with angiographically documented coronary disease. Patients were randomly assigned to receive moderate treatment (40 mg of pravastatin orally per day) or intensive treatment (80 mg of atorvastatin orally per day). Ultrasonography was repeated after 18 months to measure the progression of atherosclerosis. Lipoprotein and CRP levels were measured at baseline and follow-up.

Results In the group as a whole, the mean LDL cholesterol level was reduced from 150.2 mg per deciliter (3.88 mmol per liter) at baseline to 94.5 mg per deciliter (2.44 mmol per liter) at 18 months (P<0.001), and the geometric mean CRP level decreased from 2.9 to 2.3 mg per liter (P<0.001). The correlation between the reduction in LDL cholesterol levels and that in CRP levels was weak but significant in the group as a whole (r=0.13, P=0.005), but not in either treatment group alone. In univariate analyses, the percent change in the levels of LDL cholesterol, CRP, apolipoprotein B-100, and non–high-density lipoprotein cholesterol were related to the rate of progression of atherosclerosis. After adjustment for the reduction in these lipid levels, the decrease in CRP levels was independently and significantly correlated with the rate of progression. Patients with reductions in both LDL cholesterol and CRP that were greater than the median had significantly slower rates of progression than patients with reductions in both biomarkers that were less than the median (P=0.001).

Conclusions For patients with coronary artery disease, the reduced rate of progression of atherosclerosis associated with intensive statin treatment, as compared with moderate statin treatment, is significantly related to greater reductions in the levels of both atherogenic lipoproteins and CRP.

Source Information

From the Cleveland Clinic Foundation, Cleveland (S.E.N., E.M.T., P.S., T.C.); Pfizer, New York (W.J.S., J.T., J.O.); Ohio State University Medical Center, Columbus (R.D.M.); North Ohio Heart Care, Elyria (C.O.); and Brigham and Women's Hospital, Boston (P.G.).

Address reprint requests to Dr. Nissen at the Department of Cardiovascular Medicine, Cleveland Clinic Foundation, 9500 Euclid Ave., Cleveland, OH 44195, or at nissens{at}ccf.org.

Full Text of this Article

This article has been cited by other articles:

• Eldor, R., Raz, I. (2009). American Diabetes Association Indications for Statins in Diabetes: Is there evidence?. Diabetes Care 32: S384-S391 [Full Text]  
• Klingenberg, R., Hansson, G. K. (2009). Treating inflammation in atherosclerotic cardiovascular disease: emerging therapies. Eur Heart J 0: ehp477v1-ehp477 [Abstract] [Full Text]  
• Buckley, D. I., Fu, R., Freeman, M., Rogers, K., Helfand, M. (2009). C-Reactive Protein as a Risk Factor for Coronary Heart Disease: A Systematic Review and Meta-analyses for the U.S. Preventive Services Task Force. ANN INTERN MED 151: 483-495 [Abstract] [Full Text]  
• Helfand, M., Buckley, D. I., Freeman, M., Fu, R., Rogers, K., Fleming, C., Humphrey, L. L. (2009). Emerging Risk Factors for Coronary Heart Disease: A Summary of Systematic Reviews Conducted for the U.S. Preventive Services Task Force. ANN INTERN MED 151: 496-507 [Abstract] [Full Text]  
• Bernstein, I. M., Damron, D., Schonberg, A. L., Shapiro, R. (2009). The Relationship of Plasma Volume, Sympathetic Tone, and Proinflammatory Cytokines in Young Healthy Nonpregnant Women. Reproductive Sciences 16: 980-985 [Abstract]  
• Nasu, K., Tsuchikane, E., Katoh, O., Tanaka, N., Kimura, M., Ehara, M., Kinoshita, Y., Matsubara, T., Matsuo, H., Asakura, K., Asakura, Y., Terashima, M., Takayama, T., Honye, J., Hirayama, A., Saito, S., Suzuki, T. (2009). Effect of Fluvastatin on Progression of Coronary Atherosclerotic Plaque Evaluated by Virtual Histology Intravascular Ultrasound. J Am Coll Cardiol Intv 2: 689-696 [Abstract] [Full Text]  
• Zulli, A., Lau, E., Wijaya, B. P.P., Jin, X., Sutarga, K., Schwartz, G. D., Learmont, J., Wookey, P. J., Zinellu, A., Carru, C., Hare, D. L. (2009). High Dietary Taurine Reduces Apoptosis and Atherosclerosis in the Left Main Coronary Artery: Association With Reduced CCAAT/Enhancer Binding Protein Homologous Protein and Total Plasma Homocysteine but not Lipidemia. Hypertension 53: 1017-1022 [Abstract] [Full Text]  
• Ridker, P. M (2009). The JUPITER Trial: Results, Controversies, and Implications for Prevention. Circ Cardiovasc Qual Outcomes 2: 279-285 [Full Text]  
• Shen, J., Ordovas, J. M. (2009). Impact of Genetic and Environmental Factors on hsCRP Concentrations and Response to Therapeutic Agents. Clin. Chem. 55: 256-264 [Abstract] [Full Text]  
• Mora, S., Musunuru, K., Blumenthal, R. S. (2009). The Clinical Utility of High-Sensitivity C-Reactive Protein in Cardiovascular Disease and the Potential Implication of JUPITER on Current Practice Guidelines. Clin. Chem. 55: 219-228 [Abstract] [Full Text]  
• Ridker, P. M (2009). C-Reactive Protein: Eighty Years from Discovery to Emergence as a Major Risk Marker for Cardiovascular Disease. Clin. Chem. 55: 209-215 [Full Text]  
• Schumacher, W., Cockcroft, J., Timpson, N. J., McEniery, C. M., Gallacher, J., Rumley, A., Lowe, G., Smith, G. D., Wilkinson, I. B., Ben-Shlomo, Y. (2009). Association Between C-Reactive Protein Genotype, Circulating Levels, and Aortic Pulse Wave Velocity. Hypertension 53: 150-157 [Abstract] [Full Text]  
• Ganz, P., Hsue, P. Y. (2009). Individualized approach to the management of coronary heart disease identifying the nonresponders before it is too late.. J Am Coll Cardiol 53: 331-333 [Full Text]  
• Grammer, T. B., Marz, W., Renner, W., Bohm, B. O., Hoffmann, M. M. (2009). C-reactive protein genotypes associated with circulating C-reactive protein but not with angiographic coronary artery disease: the LURIC study. Eur Heart J 30: 170-182 [Abstract] [Full Text]  
• SHISHEHBOR, M. H., HAZEN, S. L. (2009). JUPITER to Earth: A statin helps people with normal LDL-C and high hs-CRP, but what does it mean?. Cleveland Clinic Journal of Medicine 76: 37-44 [Abstract] [Full Text]  
• Sathyapalan, T., Kilpatrick, E. S., Coady, A.-M., Atkin, S. L. (2009). The Effect of Atorvastatin in Patients with Polycystic Ovary Syndrome: A Randomized Double-Blind Placebo-Controlled Study. J. Clin. Endocrinol. Metab. 94: 103-108 [Abstract] [Full Text]  
• Hamm, C. W., Möllmann, H., Bassand, J.-P., van de Werf, F. (2009). CHAPTER 16 Acute Coronary Syndromes. ESC Textbook of Cardiovascular Medicine 2: med-9780199566990-chapter-med-9780199566990-chapter [Abstract] [Full Text]  
• Gronros, J., Wikstrom, J., Brandt-Eliasson, U., Forsberg, G. B., Behrendt, M., Hansson, G. I., Gan, L. M. (2008). Effects of rosuvastatin on cardiovascular morphology and function in an ApoE-knockout mouse model of atherosclerosis. Am. J. Physiol. Heart Circ. Physiol. 295: H2046-H2053 [Abstract] [Full Text]  
• Isma, N., Barani, J., Mattiasson, I., Lindblad, B., Gottsater, A. (2008). Lipid-Lowering Therapy is Related to Inflammatory Markers and 3-Year Mortality in Patients With Critical Limb Ischemia. ANGIOLOGY 59: 542-548 [Abstract]  
• Cayley, W. E. (2008). Monitoring Cholesterol Levels: Understanding Variance and Finding the Most Useful Data. ANN INTERN MED 149: 436-437 [Full Text]  
• Adam, O., Neuberger, H.-R., Bohm, M., Laufs, U. (2008). Prevention of Atrial Fibrillation With 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors. Circulation 118: 1285-1293 [Full Text]  
• Bonaca, M. P., Morrow, D. A. (2008). Defining a Role for Novel Biomarkers in Acute Coronary Syndromes. Clin. Chem. 54: 1424-1431 [Abstract] [Full Text]  
• Fresco, C. (2008). Pioglitazone vs Glimepiride in the PERISCOPE Trial. JAMA 300: 787-787 [Full Text]  
• Young, D. P., Kushner, I., Samols, D. (2008). Binding of C/EBP{beta} to the C-Reactive Protein (CRP) Promoter in Hep3B Cells Is Associated with Transcription of CRP mRNA. J. Immunol. 181: 2420-2427 [Abstract] [Full Text]  
• Choi, H. C., Song, P., Xie, Z., Wu, Y., Xu, J., Zhang, M., Dong, Y., Wang, S., Lau, K., Zou, M.-H. (2008). Reactive Nitrogen Species Is Required for the Activation of the AMP-activated Protein Kinase by Statin in Vivo. J. Biol. Chem. 283: 20186-20197 [Abstract] [Full Text]  
• Caplan, L. R. (2008). A 70-Year-Old Man With a Transient Ischemic Attack: Review of Internal Carotid Artery Stenosis. JAMA 300: 81-90 [Abstract] [Full Text]  
• TAYLOR, A. J. (2008). Given the ENHANCE trial results, ezetimibe is still unproven. Cleveland Clinic Journal of Medicine 75: 497-506 [Full Text]  
• Sin, D. D., Man, S. F. P. (2008). Biomarkers in COPD: Are We There Yet?. Chest 133: 1296-1298 [Full Text]  
• Yasue, H., Mizuno, Y., Harada, E., Itoh, T., Nakagawa, H., Nakayama, M., Ogawa, H., Tayama, S., Honda, T., Hokimoto, S., Ohshima, S., Hokamura, Y., Kugiyama, K., Horie, M., Yoshimura, M., Harada, M., Uemura, S., Saito, Y., for the SCAST (Statin and Coronary Artery Spasm Tr, (2008). Effects of a 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor, Fluvastatin, on Coronary Spasm After Withdrawal of Calcium-Channel Blockers. J Am Coll Cardiol 51: 1742-1748 [Abstract] [Full Text]  
• Sipahi, I, Tuzcu, E M, Moon, K-W, Nicholls, S J, Schoenhagen, P, Zhitnik, J, Crowe, T D, Kapadia, S, Nissen, S E (2008). Do the extent and direction of arterial remodelling predict subsequent progression of coronary atherosclerosis? A serial intravascular ultrasound study. Heart 94: 623-627 [Abstract] [Full Text]  
• Mohler, E. R. III, Ballantyne, C. M., Davidson, M. H., Hanefeld, M., Ruilope, L. M., Johnson, J. L., Zalewski, A., for the Darapladib Investigators, (2008). The Effect of Darapladib on Plasma Lipoprotein-Associated Phospholipase A2 Activity and Cardiovascular Biomarkers in Patients With Stable Coronary Heart Disease or Coronary Heart Disease Risk Equivalent: The Results of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Study. J Am Coll Cardiol 51: 1632-1641 [Abstract] [Full Text]  
• Nissen, S. E., Nicholls, S. J., Wolski, K., Nesto, R., Kupfer, S., Perez, A., Jure, H., De Larochelliere, R., Staniloae, C. S., Mavromatis, K., Saw, J., Hu, B., Lincoff, A. M., Tuzcu, E. M., for the PERISCOPE Investigators, (2008). Comparison of Pioglitazone vs Glimepiride on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes: The PERISCOPE Randomized Controlled Trial. JAMA 299: 1561-1573 [Abstract] [Full Text]  
• Steg, P. G., Marre, M. (2008). Does PERISCOPE Provide a New Perspective on Diabetic Treatment?. JAMA 299: 1603-1604 [Full Text]  
• Nissen, S. E., Nicholls, S. J., Wolski, K., Rodes-Cabau, J., Cannon, C. P., Deanfield, J. E., Despres, J.-P., Kastelein, J. J. P., Steinhubl, S. R., Kapadia, S., Yasin, M., Ruzyllo, W., Gaudin, C., Job, B., Hu, B., Bhatt, D. L., Lincoff, A. M., Tuzcu, E. M., for the STRADIVARIUS Investigators, (2008). Effect of Rimonabant on Progression of Atherosclerosis in Patients With Abdominal Obesity and Coronary Artery Disease: The STRADIVARIUS Randomized Controlled Trial. JAMA 299: 1547-1560 [Abstract] [Full Text]  
• Murphy, D. M., Forrest, I. A., Corris, P. A., Johnson, G. E., Small, T., Jones, D., Fisher, A. J., Egan, J. J., Cawston, T. E., Ward, C., Lordan, J. L. (2008). Simvastatin attenuates release of neutrophilic and remodeling factors from primary bronchial epithelial cells derived from stable lung transplant recipients. Am. J. Physiol. Lung Cell. Mol. Physiol. 294: L592-L599 [Abstract] [Full Text]  
• Packard, R. R. S., Libby, P. (2008). Inflammation in Atherosclerosis: From Vascular Biology to Biomarker Discovery and Risk Prediction. Clin. Chem. 54: 24-38 [Abstract] [Full Text]  
• Stern, S. (2008). Are We Getting Nearer to Screening for Atherosclerosis?. Circulation 117: 122-126 [Full Text]  
• Szwast, S. J., Hendrie, H. C., Lane, K. A., Gao, S., Taylor, S. E., Unverzagt, F., Murrell, J., Deeg, M., Ogunniyi, A., Farlow, M. R., Hall, K. S. (2007). Association of statin use with cognitive decline in elderly African Americans. Neurology 69: 1873-1880 [Abstract] [Full Text]  
• Gortney, J. S., Sanders, R. M. (2007). Impact of C-reactive protein on treatment of patients with cardiovascular disease. Am J Health Syst Pharm 64: 2009-2016 [Abstract] [Full Text]  
• Boekhoorn, S. S., Vingerling, J. R., Witteman, J. C. M., Hofman, A., de Jong, P. T. V. M. (2007). C-reactive Protein Level and Risk of Aging Macula Disorder: The Rotterdam Study. Arch Ophthalmol 125: 1396-1401 [Abstract] [Full Text]  
• Li, Y., Schellhorn, H. E. (2007). New Developments and Novel Therapeutic Perspectives for Vitamin C. J. Nutr. 137: 2171-2184 [Abstract] [Full Text]  
• Okura, H., Taguchi, H., Kubo, T., Toda, I., Yoshiyama, M., Yoshikawa, J., Yoshida, K. (2007). Impact of arterial remodelling and plaque rupture on target and non-target lesion revascularisation after stent implantation in patients with acute coronary syndrome: an intravascular ultrasound study. Heart 93: 1219-1225 [Abstract] [Full Text]  
• Momin, A., Melikian, N., Wheatcroft, S. B., Grieve, D., John, L. C., El Gamel, A., Marrinan, M. T., Desai, J. B., Driver, C., Sherwood, R., Shah, A. M., Kearney, M. T. (2007). The association between saphenous vein endothelial function, systemic inflammation, and statin therapy in patients undergoing coronary artery bypass surgery. J. Thorac. Cardiovasc. Surg. 134: 335-341 [Abstract] [Full Text]  
• Jialal, I., Miguelino, E., Griffen, S. C., Devaraj, S. (2007). Concomitant Reduction of Low-Density Lipoprotein-Cholesterol and Biomarkers of Inflammation with Low-Dose Simvastatin Therapy in Patients with Type 1 Diabetes. J. Clin. Endocrinol. Metab. 92: 3136-3140 [Abstract] [Full Text]  
• Afilalo, J., Majdan, A. A, Eisenberg, M. J (2007). Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomised controlled trials. Heart 93: 914-921 [Abstract] [Full Text]  
• Yu, C.-M., Zhang, Q., Lam, L., Lin, H., Kong, S.-L., Chan, W., Fung, J. W.-H., Cheng, K. K K, Chan, I. H.-S., Lee, S. W.-L., Sanderson, J. E, Lam, C. W.-K. (2007). Comparison of intensive and low-dose atorvastatin therapy in the reduction of carotid intimal-medial thickness in patients with coronary heart disease. Heart 93: 933-939 [Abstract] [Full Text]  
• Sipahi, I., Tuzcu, E. M., Wolski, K. E., Nicholls, S. J., Schoenhagen, P., Hu, B., Balog, C., Shishehbor, M., Magyar, W. A., Crowe, T. D., Kapadia, S., Nissen, S. E. (2007). {beta}-Blockers and Progression of Coronary Atherosclerosis: Pooled Analysis of 4 Intravascular Ultrasonography Trials. ANN INTERN MED 147: 10-18 [Abstract] [Full Text]  
• Ridker, P. M. (2007). C-Reactive Protein and the Prediction of Cardiovascular Events Among Those at Intermediate Risk: Moving an Inflammatory Hypothesis Toward Consensus. J Am Coll Cardiol 49: 2129-2138 [Abstract] [Full Text]  
• Kolodgie, F. D., Narula, J., Yuan, C., Burke, A. P., Finn, A. V., Virmani, R. (2007). Elimination of Neoangiogenesis for Plaque Stabilization: Is There a Role for Local Drug Therapy?. J Am Coll Cardiol 49: 2093-2101 [Abstract] [Full Text]  
• Tuzcu, E. M., Nicholls, S. J. (2007). Statins: Targeting Inflammation by Lowering Low-Density Lipoprotein?. J Am Coll Cardiol 49: 2010-2012 [Full Text]  
• NACB WRITING GROUP MEMBERS, , Morrow, D. A., Cannon, C. P., Jesse, R. L., Newby, L. K., Ravkilde, J., Storrow, A. B., Wu, A. H.B., Christenson, R. H. (2007). National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Characteristics and Utilization of Biochemical Markers in Acute Coronary Syndromes. Circulation 115: e356-e375 [Full Text]  
• Bisoendial, R. J., Kastelein, J. J. P., Peters, S. L. M., Levels, J. H. M., Birjmohun, R., Rotmans, J. I., Hartman, D., Meijers, J. C. M., Levi, M., Stroes, E. S. G. (2007). Effects of CRP infusion on endothelial function and coagulation in normocholesterolemic and hypercholesterolemic subjects. J. Lipid Res. 48: 952-960 [Abstract] [Full Text]  
• Frost, F. J., Petersen, H., Tollestrup, K., Skipper, B. (2007). Influenza and COPD Mortality Protection as Pleiotropic, Dose-Dependent Effects of Statins. Chest 131: 1006-1012 [Abstract] [Full Text]  
• NACB WRITING GROUP MEMBERS, , Morrow, D. A., Cannon, C. P., Jesse, R. L., Newby, L. K., Ravkilde, J., Storrow, A. B., Wu, A. H.B., Christenson, R. H., NACB COMMITTEE MEMBERS, , Christenson, R. H., Apple, F. S., Cannon, C. P., Francis, G., Jesse, R. L., Morrow, D. A., Newby, L. K., Ravkilde, J., Storrow, A. B., Tang, W., Wu, A. H.B. (2007). National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Characteristics and Utilization of Biochemical Markers in Acute Coronary Syndromes. Clin. Chem. 53: 552-574 [Full Text]  
• Nissen, S. E., Tardif, J.-C., Nicholls, S. J., Revkin, J. H., Shear, C. L., Duggan, W. T., Ruzyllo, W., Bachinsky, W. B., Lasala, G. P., Tuzcu, E. M., the ILLUSTRATE Investigators, (2007). Effect of Torcetrapib on the Progression of Coronary Atherosclerosis. NEJM 356: 1304-1316 [Abstract] [Full Text]  
• Revkin, J. H., Shear, C. L., Pouleur, H. G., Ryder, S. W., Orloff, D. G. (2007). Biomarkers in the Prevention and Treatment of Atherosclerosis: Need, Validation, and Future. Pharmacol. Rev. 59: 40-53 [Abstract] [Full Text]  
• Pulido, J. S., McConnell, J. P., Peterson, L. M., Highsmith, W. E., Lennon, R. J., Bryant, S. C., Berger, P. B., Somers, V. (2007). Relationship Between Age-Related Macular Degeneration-Associated Variants of Complement Factor H and LOC387715 With Coronary Artery Disease. Mayo Clin Proc. 82: 301-307 [Abstract] [Full Text]  
• Nicholls, S. J., Tuzcu, E. M., Sipahi, I., Grasso, A. W., Schoenhagen, P., Hu, T., Wolski, K., Crowe, T., Desai, M. Y., Hazen, S. L., Kapadia, S. R., Nissen, S. E. (2007). Statins, High-Density Lipoprotein Cholesterol, and Regression of Coronary Atherosclerosis. JAMA 297: 499-508 [Abstract] [Full Text]  
• Belay, B., Belamarich, P. F., Tom-Revzon, C. (2007). The Use of Statins in Pediatrics: Knowledge Base, Limitations, and Future Directions. Pediatrics 119: 370-380 [Abstract] [Full Text]  
• Jeevanantham, V., Singh, N., Izuora, K., D'souza, J. P., Hsi, D. H. (2007). Correlation of High Sensitivity C-Reactive Protein and Calcific Aortic Valve Disease. Mayo Clin Proc. 82: 171-174 [Abstract] [Full Text]  
• Hanefeld, M., Marx, N., Pfutzner, A., Baurecht, W., Lubben, G., Karagiannis, E., Stier, U., Forst, T. (2007). Anti-Inflammatory Effects of Pioglitazone and/or Simvastatin in High Cardiovascular Risk Patients With Elevated High Sensitivity C-Reactive Protein: The PIOSTAT Study. J Am Coll Cardiol 49: 290-297 [Abstract] [Full Text]  
• Klein, L. W. (2007). Atherosclerosis Regression, Vascular Remodeling, and Plaque Stabilization. J Am Coll Cardiol 49: 271-273 [Full Text]  
• Liuzzo, G., Santamaria, M., Biasucci, L. M., Narducci, M., Colafrancesco, V., Porto, A., Brugaletta, S., Pinnelli, M., Rizzello, V., Maseri, A., Crea, F. (2007). Persistent Activation of Nuclear Factor Kappa-B Signaling Pathway in Patients With Unstable Angina and Elevated Levels of C-Reactive Protein: Evidence for a Direct Proinflammatory Effect of Azide and Lipopolysaccharide-Free C-Reactive Protein on Human Monocytes Via Nuclear Factor Kappa-B Activation. J Am Coll Cardiol 49: 185-194 [Abstract] [Full Text]  
• Capuzzi, D. M., Freeman, J. S. (2007). C-Reactive Protein and Cardiovascular Risk in the Metabolic Syndrome and Type 2 Diabetes: Controversy and Challenge. Clin. Diabetes 25: 16-22 [Abstract] [Full Text]  
• Chen, H.-h., Hosken, B. D., Huang, M., Gaubatz, J. W., Myers, C. L., Macfarlane, R. D., Pownall, H. J., Yang, C.-y. (2007). Electronegative LDLs from familial hypercholesterolemic patients are physicochemically heterogeneous but uniformly proapoptotic. J. Lipid Res. 48: 177-184 [Abstract] [Full Text]  
• Blanco-Colio, L. M., Martin-Ventura, J. L., de Teresa, E., Farsang, C., Gaw, A., Gensini, G., Leiter, L. A., Langer, A., Martineau, P., Hernandez, G., Egido, J., on behalf of the ACTFAST investigators, (2007). Increased Soluble Fas Plasma Levels in Subjects at High Cardiovascular Risk: Atorvastatin on Inflammatory Markers (AIM) Study, a Substudy of ACTFAST. Arterioscler. Thromb. Vasc. Bio. 27: 168-174 [Abstract] [Full Text]  
• Crawford, D. C., Sanders, C. L., Qin, X., Smith, J. D., Shephard, C., Wong, M., Witrak, L., Rieder, M. J., Nickerson, D. A. (2006). Genetic Variation Is Associated With C-Reactive Protein Levels in the Third National Health and Nutrition Examination Survey. Circulation 114: 2458-2465 [Abstract] [Full Text]  
• Yu, D., Murdoch, S. J, Parikh, S. J, Marcovina, S. M, Cobitz, A., Chen, H., Brunzell, J. D (2006). Rosiglitazone increases LDL particle size and buoyancy and decreases C-reactive protein in patients with type 2 diabetes on statin therapy. Diabetes and Vascular Disease Research 3: 189-196 [Abstract]  
• Persson, F., Rossing, P., Hovind, P., Stehouwer, C. D.A., Schalkwijk, C., Tarnow, L., Parving, H.-H. (2006). Irbesartan Treatment Reduces Biomarkers of Inflammatory Activity in Patients With Type 2 Diabetes and Microalbuminuria: An IRMA 2 Substudy. Diabetes 55: 3550-3555 [Abstract] [Full Text]  
• Van de Veire, N R, Philippe, J, De Winter, O, Langlois, M, Bernard, D, De Sutter, J (2006). Neurohumoral and inflammatory activation in patients with coronary artery disease treated with statins. Heart 92: 1858-1859 [Full Text]  
• Goicoechea, M., de Vinuesa, S. G., Lahera, V., Cachofeiro, V., Gomez-Campdera, F., Vega, A., Abad, S., Luno, J. (2006). Effects of Atorvastatin on Inflammatory and Fibrinolytic Parameters in Patients with Chronic Kidney Disease. J. Am. Soc. Nephrol. 17: S231-S235 [Abstract] [Full Text]  
• Waxman, S., Ishibashi, F., Muller, J. E. (2006). Detection and Treatment of Vulnerable Plaques and Vulnerable Patients: Novel Approaches to Prevention of Coronary Events. Circulation 114: 2390-2411 [Full Text]  
• Libby, P., Ridker, P. M. (2006). Inflammation and Atherothrombosis: From Population Biology and Bench Research to Clinical Practice. J Am Coll Cardiol 48: A33-A46 [Abstract] [Full Text]  
• Eldrup, N., Gronholdt, M.-L. M., Sillesen, H., Nordestgaard, B. G. (2006). Elevated Matrix Metalloproteinase-9 Associated With Stroke or Cardiovascular Death in Patients With Carotid Stenosis. Circulation 114: 1847-1854 [Abstract] [Full Text]  
• Nissen, S. E. (2006). High-Dose Statins and Atherosclerosis Regression--Reply. JAMA 296: 1837-1837 [Full Text]  
• Bos, M. J., Schipper, C. M. A., Koudstaal, P. J., Witteman, J. C.M., Hofman, A., Breteler, M. M.B. (2006). High Serum C-Reactive Protein Level Is Not an Independent Predictor for Stroke: The Rotterdam Study. Circulation 114: 1591-1598 [Abstract] [Full Text]  
• Hayward, R. A., Hofer, T. P., Vijan, S. (2006). Narrative review: lack of evidence for recommended low-density lipoprotein treatment targets: a solvable problem.. ANN INTERN MED 145: 520-530 [Abstract] [Full Text]  
• Devaraj, S., Autret, B. C, Jialal, I. (2006). Reduced-calorie orange juice beverage with plant sterols lowers C-reactive protein concentrations and improves the lipid profile in human volunteers.. Am. J. Clin. Nutr. 84: 756-761 [Abstract] [Full Text]  
• Sirtori, C. R. (2006). HDL and the progression of atherosclerosis: new insights. Eur Heart J Suppl 8: F4-F9 [Abstract] [Full Text]  
• Hulten, E., Jackson, J. L., Douglas, K., George, S., Villines, T. C. (2006). The Effect of Early, Intensive Statin Therapy on Acute Coronary Syndrome: A Meta-analysis of Randomized Controlled Trials.. Arch Intern Med 166: 1814-1821 [Abstract] [Full Text]  
• Mehra, R., Storfer-Isser, A., Kirchner, H. L., Johnson, N., Jenny, N., Tracy, R. P., Redline, S. (2006). Soluble interleukin 6 receptor: a novel marker of moderate to severe sleep-related breathing disorder.. Arch Intern Med 166: 1725-1731 [Abstract] [Full Text]